News

Sistemic and leading CDMO, Progenitor Cell Therapy (PCT) initiate study on novel stem cell characterisation technology

Sistemic Limited (Sistemic), the miRNA profiling company with facilities in Glasgow, Scotland and Boston, announced today the signature of an agreement to allow Progenitor Cell Therapy (PCT) to initiate evaluation studies on Sistemic’s SistemQC™ stem cell characterisation technology.

Sistemic Poster Winner at World Stem Cell Summit 2012

Dr. David Mallinson, Senior Staff scientist at Sistemic attended the World Stem Cell Summit in West Palm Beach, Florida, on December 3-5th 2012. We are thrilled to announce that David won the Best Poster of the many posters that were presented over the 3 days of the busy international meeting which was judged by a prestigious panel of Cell Therapy Experts. So well done David!

EMD Millipore and Sistemic Collaborate to Identify Control Markers for Stem Cell Production

EMD Millipore, the Life Science division of Merck KGaA, Darmstadt, Germany, today announced a new initiative with Sistemic Ltd., a leading provider of microRNA-based problem-solving services and kit-based products.

Sistemic Are Hiring!

We are looking for 2 life sciences graduates to support development of our new SistemPSCCheck™ v1.0 service product. These are 12 month placements, with the potential to develop into a permanent roles. For full information, please visit Scotgrad via the links below:

Sistemic will be attending the 4th Cell Therapy Conference: Manufacturing and Testing of Pluripotent Stem Cells

Sistemic will be attending the 4th Cell Therapy Conference: Manufacturing and Testing of Pluripotent Stem Cells in June to highlight the development of SistemPSCCheck™ - the world’s first commercial assay for assessment of pluripotent stem cell contamination in derived cell therapy products

Sistemic will be attending Phacilitate Cell & Gene Therapy World and the World Stem Cell Summit

GLASGOW, SCOTLAND Sistemic will be attending Phacilitate Cell & Gene Therapy World and the World Stem Cell Summit in January to highlight the development of their assay for assessment of pluripotent stem cell contamination in derived cell therapy products

Sistemic announce significant progress of pluripotent stem cell contamination technology in derived cell therapy products

Glasgow, SCOTLAND. Sistemic Ltd. is excited to announce significant progress with the development of a miRNA-based assay for assessment of pluripotent stem cell (PSC) contamination in derived cell therapy products. The development is being undertaken in conjunction with LGC, the UK National Measurement Laboratory and Designated Institute for chemical and bio-measurement.

Cell & Gene Meeting on the Mesa 2017

We are glad to accounce we will be attending this years Cell & Gene Meeting on the Mesa. If you would like to organise partnering you can contact us at info@sistemic.co.uk with your request.

Previous Pause Next

Applications & Case Studies

Recent Tweets

We are hiring! Product Service Support Position (Placement ID: CJCTGUEKKF): https://t.co/sERDjHVqaY R&D Support P… https://t.co/clwUaYy7dV — Tweeted: Fri, 09/28/2018 - 17:11

Current Location

News

Pages

Recent News

Applications & Case Studies

Recent Tweets